Advanced search
Publication Cover
Emerging Microbes & Infections Volume 3, 2014 - Issue 1
Submit an article Journal homepage
3,200
Views
142
CrossRef citations to date
0
Altmetric
Reviews

Persisters, persistent infections and the Yin–Yang model

Ying ZhangDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA;Key Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaCorrespondence[email protected]
Pages 1-10 | Received 23 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • Hobby GL, Meyer K, Chaffee E.Observations on the mechanism of action of penicillin. Proc Soc Exp Biol NY1942;50: 281–285.
  • Bigger JW.Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet1944;244: 497–500.
  • Moyed HS, Bertrand KP.hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol1983;155: 768–775.
  • Li Y, Zhang Y.PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob Agents Chemother2007;51: 2092–2099.
  • Zhang Y.Advances in the treatment of tuberculosis. Clin Pharmacol Ther2007;82: 595–600.
  • Gefen O, Balaban NQ.The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol Rev2009;33: 704–717.
  • Allison KR, Brynildsen MP, Collins JJ.Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol2011;14: 593–598.
  • Zhang Y, Yew WW, Barer MR.Targeting persisters for tuberculosis control. Antimicrob Agents Chemother2012;56: 2223–2230.
  • Ma C, Sim S, Shi W, Du L, Xing D, Zhang Y.Energy production genes sucB and ubiF are involved in persister survival and tolerance to multiple antibiotics and stresses in Escherichia coli. FEMS Microbiol Lett2010;303: 33–40.
  • Joers A, Kaldalu N, Tenson T.The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy. J Bacteriol2010;192: 3379–3384.
  • Hu Y, Coates AR.Transposon mutagenesis identifies genes which control antimicrobial drug tolerance in stationary-phase Escherichia coli. FEMS Microbiol Lett2005;243: 117–124.
  • Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K.Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett2004;230: 13–18.
  • Lewis K.Persister cells. Annu Rev Microbiol2010;64: 357–372.
  • Xu HS, Roberts N, Singleton FL, Attwell RW, Grimes DJ, Colwell RR.Survival and viability of nonculturable Escherichia coli and Vibrio cholerae in the estuarine and marine environment. Microbial Ecology1982;8: 313–323.
  • Hobby GL, Auerbach O, Lenert TF, Small MJ, Comer JV.The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans. Am Rev Tuberc1954;70: 191–218.
  • Zhang Y, Yang Y, Woods A, Cotter RJ, Sun Z.Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem Biophys Res Commun2001;284: 542–547.
  • Greenwood D.Phenotypic resistance to antimicrobial agents. J Antimicrob Chemother1985;15: 653–655.
  • Zhang Y.Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci2004;9: 1136–1156.
  • Zhou J, Zhang Y.Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle2008;7: 1360–1370.
  • Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S.Bacterial persistence as a phenotypic switch. Science2004;305: 1622–1625.
  • Stewart B, Rozen DE.Genetic variation for antibiotic persistence in Escherichia coli. Evolution2012;66: 933–939.
  • Glover WA, Yang Y, Zhang Y.Insights into the molecular basis of L-form formation and survival in Escherichia coli. PLoS ONE2009;4: e7316.
  • Domingue GJ.Demystifying pleomorphic forms in persistence and expression of disease: are they bacteria, and is peptidoglycan the solution? Discov Med2010;10: 234–246.
  • Kim JS, Heo P, Yang TJ, et al.Bacterial persisters tolerate antibiotics by not producing hydroxyl radicals. Biochem Biophys Res Commun2011;413: 105–110.
  • Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BP, Thevissen K.Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob Agents Chemother2011;55: 4033–4037.
  • Gerdes K, Maisonneuve E.Bacterial persistence and toxin–antitoxin loci. Annu Rev Microbiol2012;66: 103–123.
  • Li J, Ji L, Shi W, Xie J, Zhang Y.Trans-translation mediates tolerance to multiple antibiotics and stresses in Escherichia coli. J Antimicrob Chemother2013;68: 2477–2481.
  • Sarathy J, Dartois V, Dick T, Gengenbacher M.Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother2013;57: 1648–1653.
  • Fung DK, Chan EW, Chin ML, Chan RC.Delineation of a bacterial starvation stress response network which can mediate antibiotic tolerance development. Antimicrob Agents Chemother2010;54: 1082–1093.
  • Amato SM, Orman MA, Brynildsen MP.Metabolic control of persister formation in Escherichia coli. Mol Cell2013;50: 475–487.
  • Korch SB, Henderson TA, Hill TM.Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol2003;50: 1199–1213.
  • Leung V, Levesque CM.A stress-inducible quorum-sensing peptide mediates the formation of persister cells with noninherited multidrug tolerance. J Bacteriol2012;194: 2265–2274.
  • Wu Y, Vulic M, Keren I, Lewis K.Role of oxidative stress in persister tolerance. Antimicrob Agents Chemother2012;56: 4922–4926.
  • Nguyen D, Joshi-Datar A, Lepine F et al.Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science2011;334: 982–986.
  • Shatalin K, Shatalina E, Mironov A, Nudler E.H2S: a universal defense against antibiotics in bacteria. Science2011;334: 986–990.
  • Gusarov I, Shatalin K, Starodubtseva M, Nudler E.Endogenous nitric oxide protects bacteria against a wide spectrum of antibiotics. Science2009;325: 1380–1384.
  • Dorr T, Vulic M, Lewis K.Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol2010;8: e1000317.
  • Kwan BW, Valenta JA, Benedik MJ, Wood TK.Arrested protein synthesis increases persister-like cell formation. Antimicrob Agents Chemother2013;57: 1468–1473
  • Hansen S, Lewis K, Vulic M.Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob Agents Chemother2008;52: 2718–2726.
  • Hong SH, Wang X, O’Connor HF, Benedik MJ, Wood TK.Bacterial persistence increases as environmental fitness decreases. Microb Biotechnol2012;5: 509–522.
  • Luidalepp H, Joers A, Kaldalu N, Tenson T.Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence. J Bacteriol2011;193: 3598–3605.
  • Levin-Reisman I, Gefen O, Fridman O et al.Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes. Nat Methods2010;7: 737–739.
  • Scherrer R, Moyed HS.Conditional impairment of cell division and altered lethality in hipA mutants of Escherichia coli K-12. J Bacteriol1988;170: 3321–3326.
  • Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ.Nongenetic individuality in the host–phage interaction. PLoS Biol2008;6: e120.
  • Wakamoto Y, Dhar N, Chait R, et al.Dynamic persistence of antibiotic-stressed mycobacteria. Science2013;339: 91–95.
  • Zhang Y, Heym B, Allen B, Young D, Cole S.The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature1992;358: 591–593.
  • Stricker RB, Johnson L.The pain of chronic Lyme disease: moving the discourse backward? FASEB J2011;25: 4085–4087.
  • McDermott W.Microbial persistence. Yale J Biol Med1958;30: 257–291.
  • Fauvart M, de Groote VN, Michiels J.Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol2011;60: 699–709.
  • McDermott W.Microbial persistence. Harvey Lecture1969;63: 1–31.
  • Barry CE 3rd, Boshoff HI, Dartois V et al.The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol2009;7: 845–855.
  • Mulcahy LR, Burns JL, Lory S, Lewis K.Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol2010;192: 6191–6199.
  • Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ.Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother2010;54: 643–651.
  • Embers ME, Barthold SW, Borda JT et al.Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE2012;7: e29914.
  • Finzi D, Blankson J, Siliciano JD et al.Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med1999;5: 512–517.
  • Zoulim F.New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol2005;42: 302–308.
  • Masaki T, Qu J, Cholewa-Waclaw J, Burr K, Raaum R, Rambukkana A.Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection. Cell2013;152: 51–67.
  • Das B, Kashino SS, Pulu I et al.CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med2013;5: 170ra13.
  • Veening JW, Smits WK, Kuipers OP.Bistability, epigenetics, and bet-hedging in bacteria. Annu Rev Microbiol2008;62: 193–210.
  • Rotem E, Loinger A, Ronin I et al.Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence. Proc Natl Acad Sci USA2010;107: 12541–12546.
  • Klapper I, Gilbert P, Ayati BP, Dockery J, Stewart PS.Senescence can explain microbial persistence. Microbiology2007;153: 3623–3630.
  • Girgis HS, Harris K, Tavazoie S.Large mutational target size for rapid emergence of bacterial persistence. Proc Natl Acad Sci USA2012;109: 12740–12745.
  • Spoering AL, Vulic M, Lewis K.GlpD and PlsB participate in persister cell formation in Escherichia coli. J Bacteriol2006;188: 5136–5144.
  • Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, Lewis K.Persisters: a distinct physiological state of E. coli. BMC Microbiol2006;6: 53.
  • Betts J, Lukey P, Robb L, McAdam R, Duncan K.Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol2002;43: 717–731.
  • Buckles EL, Wang X, Lockatell CV, Johnson DE, Donnenberg MS.PhoU enhances the ability of extraintestinal pathogenic Escherichia coli strain CFT073 to colonize the murine urinary tract. Microbiology2006;152: 153–160.
  • Shi W, Zhang Y.PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis. J Antimicrob Chemother2010;65: 1237–1242.
  • Dahl JL, Kraus CN, Boshoff HI et al.The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA2003;100: 10026–10031.
  • Norton JP, Mulvey MA.Toxin–antitoxin systems are important for niche-specific colonization and stress resistance of uropathogenic Escherichia coli. PLoS Pathog2012;8: e1002954.
  • Clarke MF, Dick JE, Dirks PB et al.Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res2006;66: 9339–9344.
  • Holzman D. Genetic switch plays key role, converting ordinary to “persister” bacteria.Washington, DC: Microbe Magazine, 2007.Available at http://forms.asm.org/microbe/index.asp?bid551533 (accessed 24 March 2013).
  • Allan EJ, Hoischen C, Gumpert J.Bacterial L-forms. Adv Appl Microbiol2009;68: 1–39.
  • Zhou J, Wulfkuhle J, Zhang H et al.Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA2007;104: 16158–16163.
  • Pietras A.Cancer stem cells in tumor heterogeneity. Adv Cancer Res2011;112: 255–281.
  • Glickman MS, Sawyers CL.Converting cancer therapies into cures: lessons from infectious diseases. Cell2012;148: 1089–1098.
  • Dawson CC, Intapa C, Jabra-Rizk MA.“Persisters”: survival at the cellular level. PLoS Pathog2011;7: e1002121.
  • Ben-Jacob E, Coffey DS, Levine H.Bacterial survival strategies suggest rethinking cancer cooperativity. Trends Microbiol2012;20: 403–410.
  • Zhang Y, Mitchison D.The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis2003;7: 6–21.
  • Zhang Y, Permar S, Sun Z.Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol2002;51: 42–49.
  • Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z.Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother2003;52: 790–795.
  • Shi W, Zhang X, Jiang X et al.Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science2011;333: 1630–1632.
  • Zhang S, Chen J, Shi W, Liu W, Zhang WH, Zhang Y.Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect2013;2: e34.
  • Deye GA, Gettayacamin M, Hansukjariya P, et al.Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Am J Trop Med Hyg2012;86: 931–935.
  • Wade MM, Zhang Y.Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother2006;58: 936–941.
  • Coates AR, Hu Y.Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci2008;29: 143–150.
  • Nathan C.Fresh approaches to anti-infective therapies. Sci Transl Med2012;4: 140sr2.
  • Zhang Y.The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol2005;45: 529–564.
  • Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB, Young M.A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol2002;46: 623–635.
  • Orman MA, Brynildsen MP.Establishment of a method to rapidly assay bacterial persister metabolism. Antimicrob Agents Chemother2013;57: 4398–4409.
  • Somoskovi A, Wade MM, Sun Z, Zhang Y.Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother2004;53: 192–196.
  • Byrne ST, Denkin SM, Zhang Y.Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother2007;59: 313–316.
  • Allison KR, Brynildsen MP, Collins JJ.Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature2011;473:216–220.
  • Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT.Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA2012;109: 12147–12152.
  • Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ.Silver enhances antibiotic activity against gram-negative bacteria. Sci Transl Med2013;5: 190ra81.
  • Kim JS, Heo P, Yang TJ, et al.Selective killing of bacterial persisters by a single chemical compound without affecting normal antibiotic-sensitive cells. Antimicrob Agents Chemother2011;55: 5380–5383.
  • Pan J, Bahar AA, Syed H, Ren D.Reverting antibiotic tolerance of Pseudomonas aeruginosa PAO1 persister cells by (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one. PLoS ONE2012;7: e45778.
  • Aagaard C, Hoang T, Dietrich J, et al.A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med2011;17: 189–194.
  • Wang CC, Zhu B, Fan X, Gicquel B, Zhang Y.Systems approach to tuberculosis vaccine development. Respirology2013;18: 412–420.
  • Lowrie DB, Tascon RE, Bonato VL et al.Therapy of tuberculosis in mice by DNA vaccination. Nature1999;400: 269–271.
  • van Opijnen T, Bodi KL, Camilli A.Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat Methods2009;6: 767–772.
  • LaFleur MD, Kumamoto CA, Lewis K.Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother2006;50: 3839–3846.
  • Cheng Q, Kyle DE, Gatton ML.Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy? Int J Parasitol Drugs Drug Resist2012;2: 249–255.
  • Gupta PB, Chaffer CL, Weinberg RA.Cancer stem cells: mirage or reality? Nat Med2009;15: 1010–1012.
  • Gupta PB, Onder TT, Jiang G et al.Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell2009;138: 645–659.
  • Zhou JB, Zhang Y.Preclinical development of cancer stem cell drugs. Expert Opin Drug Discov2009;4: 741–752.
  • McCune RM Jr, McDermott W, Tompsett R.The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med1956;104: 763–802.
  • Andries K, Verhasselt P, Guillemont J et al.A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science2005;307: 223–227.
  • Fox W, Ellard GA, Mitchison DA.Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis1999;3: S231–S279.
  • The World Health Organization. Treatment of tuberculosis: guidelines.4th ed.Geneva: WHO, 2010.
  • Ryan FJ.Bacterial mutation in a stationary phase and the question of cell turnover. J Gen Microbiol1959;21: 530–549.
  • Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y.NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat2008;111: 419–427.
  • Zhou J, Zhang H, Gu P, Margolick JB, Yin D, Zhang Y.Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res Treat2009;115: 269–277.
  • Yuan S, Wang F, Chen G et al.Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells2013;31: 23–34.
  • Tashiro Y, Kawata K, Taniuchi A, Kakinuma K, May T, Okabe S.RelE-mediated dormancy is enhanced at high cell density in Escherichia coli. J Bacteriol2012;194: 1169–1176.
  • Kim Y, Wood TK.Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli. Biochem Biophys Res Commun2009;391: 209–213.
  • Deb C, Lee CM, Dubey VS et al.A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE2009;4: e6077.
  • Sureka K, Ghosh B, Dasgupta A, Basu J, Kundu M, Bose I.Positive feedback and noise activate the stringent response regulator rel in mycobacteria. PLoS ONE2008;3: e1771.
  • Debbia EA, Roveta S, Schito AM, Gualco L, Marchese A.Antibiotic persistence: the role of spontaneous DNA repair response. Microb Drug Resist2001;7: 335–342.
  • Dorr T, Lewis K, Vulic M.SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet2009;5: e1000760.
  • Almiron M, Link AJ, Furlong D, Kolter R.A novel DNA-binding protein with regulatory and protective roles in starved Escherichia coli. Genes Dev1992;6: 2646–2654.
  • Pandey AK, Sassetti CM.Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA2008;105: 4376–4380.
  • Adams KN, Takaki K, Connolly LE et al.Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell2011;145: 39–53.
  • Wang C, Mao Y, Yu J et al.PhoY2 of mycobacteria is required for metabolic homeostasis and stress response. J Bacteriol2013;195: 243–252.
  • Moker N, Dean CR, Tao J.Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol2010;192: 1946–1955.
  • Vega NM, Allison KR, Khalil AS, Collins JJ.Signaling-mediated bacterial persister formation. Nat Chem Biol2012;8: 431–433.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.